Cybin faces clinical trial delays, leadership changes, and cash burn concerns. Learn why CYBN's outlook has been downgraded ...

Ginger is known for its soothing effects on the stomach, and can effectively relieve nausea. It may also play a role in reducing migraine symptoms.

Artificial intelligence (AI) is rapidly transforming clinical trials by dramatically reducing timelines and costs, accelerating patient-centered drug development and creating more resilient and ...

Medpace Hldgs (NASDAQ: MEDP) will release its quarterly earnings report on Wednesday, 2025-10-22. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Medpace Hldgs to ...

The latest announcement is out from Xuanzhu Biopharmaceutical Co., Ltd. Class H ( ($HK:2575) ). Xuanzhu Biopharmaceutical Co., Ltd. announced ...

The "BioCardia Inc. (BCDA) - Product Pipeline Analysis, 2025 Update" has been added to ResearchAndMarkets.com's offering. BioCardia Inc is at the forefront of regenerative medicine, focusing on ...

Unlock the advantage of pragmatic trials and improve efficiency and real-world relevance to reduce risk and strengthen ...

Analysts estimate that Icon will report an earnings per share (EPS) of $3.22. The announcement from Icon is eagerly ...

Replimune's RP1 BLA for advanced melanoma gets FDA review, sparking REPL stock surge. Click here to read why REPL stock is ...

Q32 Bio ( ($QTTB) ) has provided an update. On October 21, 2025, Q32 Bio announced the completion of enrollment in Part B of its SIGNAL-AA Phase ...

This is a randomized, double-blind, placebo-controlled Phase II clinical trial designed to evaluate the efficacy, safety, and ...

The emphysema market is anticipated to grow steadily, fueled by a range of emerging therapies under development. Leading ...